PepGen's shares plummet 65% as mixed Phase 2 data sparks concern.

PepGen's shares have plummeted 65% after releasing mixed Phase 2 data. Despite the disappointing results, a higher dose may offer some relief. The company's shares dropped sharply yesterday and continue to fall today, making it one of the biggest losers in the market. The mixed data has raised concerns about the efficacy of PepGen's treatment.